VolitionRx Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

VolitionRx wird ein Gewinn- und Umsatzwachstum von 40.4% bzw. 52.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 44.8% pro Jahr wachsen soll.

Wichtige Informationen

40.4%

Wachstumsrate der Gewinne

44.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.8%
Wachstumsrate der Einnahmen	53.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

What Type Of Shareholders Own The Most Number of VolitionRx Limited (NYSEMKT:VNRX) Shares?

Nov 30

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:VNRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	41	-7	5	-3	2
12/31/2025	13	-22	-14	-19	3
12/31/2024	3	-30	-27	-28	4
3/31/2024	1	-35	-19	-18	N/A
12/31/2023	1	-35	-19	-18	N/A
9/30/2023	1	-34	-32	-30	N/A
6/30/2023	1	-33	-30	-29	N/A
3/31/2023	0	-31	-29	-28	N/A
12/31/2022	0	-30	-17	-15	N/A
9/30/2022	0	-31	-15	-14	N/A
6/30/2022	0	-30	-13	-12	N/A
3/31/2022	0	-28	-12	-11	N/A
12/31/2021	0	-27	-22	-21	N/A
9/30/2021	0	-24	-21	-19	N/A
6/30/2021	0	-21	-21	-19	N/A
3/31/2021	0	-21	-20	-18	N/A
12/31/2020	0	-20	-18	-16	N/A
9/30/2020	0	-19	-17	-16	N/A
6/30/2020	0	-19	-16	-16	N/A
3/31/2020	0	-18	-15	-14	N/A
12/31/2019	0	-16	-13	-13	N/A
9/30/2019	0	-17	-14	-14	N/A
6/30/2019	N/A	-17	-15	-15	N/A
3/31/2019	N/A	-18	-15	-15	N/A
12/31/2018	N/A	-18	-15	-15	N/A
9/30/2018	N/A	-18	-15	-15	N/A
6/30/2018	N/A	-17	-14	-13	N/A
3/31/2018	N/A	-16	-14	-13	N/A
12/31/2017	N/A	-15	N/A	-12	N/A
9/30/2017	N/A	-14	N/A	-10	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-12	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-9	N/A
6/30/2016	N/A	-11	N/A	-9	N/A
3/31/2016	N/A	-10	N/A	-9	N/A
12/31/2015	N/A	-10	N/A	-9	N/A
9/30/2015	0	-8	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-6	N/A
3/31/2015	N/A	-8	N/A	-5	N/A
12/31/2014	N/A	-8	N/A	-4	N/A
9/30/2014	0	-8	N/A	-4	N/A
6/30/2014	N/A	-3	N/A	-4	N/A
3/31/2014	N/A	-5	N/A	-4	N/A
12/31/2013	N/A	-4	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VNRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VNRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VNRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VNRXDie Einnahmen des Unternehmens (52.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: VNRXDie Einnahmen des Unternehmens (52.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VNRX in 3 Jahren voraussichtlich hoch sein wird

VolitionRx Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.9% to US$3.47

Consensus revenue estimates decrease by 16%, EPS upgraded

Consensus revenue estimates increase by 23%, EPS downgraded

Consensus revenue estimates fall by 43%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 22%, EPS upgraded

Recent updates

Price target decreased by 7.9% to US$3.47

Consensus revenue estimates decrease by 16%, EPS upgraded

New minor risk - Profitability

Consensus revenue estimates increase by 23%, EPS downgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

VolitionRx Limited, Annual General Meeting, Jul 02, 2024

VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech

Consensus revenue estimates fall by 43%

New minor risk - Profitability

Forecast to breakeven in 2026

Full year 2023 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited announced that it has received $0.1 million in funding

Volitionrx Limited Appoints Andrew Retter as Chief Medical Officer, Effective April 1, 2024

High number of new directors

VolitionRx Limited announced that it has received €2.5 million in funding

Consensus revenue estimates decrease by 22%, EPS upgraded

New major risk - Negative shareholders equity

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 7.2% to US$3.66

VolitionRx Limited Presents Breakthrough Liquid Biopsy Blood Test Method for Early-Stage Cancer

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

Consensus revenue estimates decrease by 45%

Forecast to breakeven in 2025

Price target decreased by 11% to US$4.94

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $7.525 million.

Price target decreased by 9.7% to US$5.21

Chief Scientific Officer recently bought US$72k worth of stock

Volitionrx Limited Announces Resignation of Dr. Jason Terrell as Chief Medical Officer

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Volition Announces the Launch of the Nu.Q(R) Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Consensus revenue estimates fall by 19%

VolitionRx Limited Appoints Mickie Henshall as Independent Director

Price target decreased to US$6.71

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 94%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited Launches its Nu.Q® Vet Cancer Test in Asia

VolitionRx Limited Appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

Consensus revenue estimates increase by 253%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2020)

Consensus revenue estimates fall to US$530.0k

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.12 loss in 2Q 2020)

VolitionRx Limited Demonstrates Promising Results in Covid-19 Risk Stratification and Disease Monitoring

VolitionRx Limited(NYSEAM:VNRX) dropped from Russell 3000E Value Index

Consensus forecasts updated

Lead Independent Director recently bought US$503k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2020)

Non-Executive Director has left the company

Consensus revenue estimates fall to US$903.7k

Full year 2020 earnings released: US$0.45 loss per share (vs US$0.41 loss in FY 2019)

Do Institutions Own VolitionRx Limited (NYSEMKT:VNRX) Shares?

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $20.000001 million.

Insider recently sold US$54k worth of stock

This Insider Has Just Sold Shares In VolitionRx Limited (NYSEMKT:VNRX)

New 90-day high: US$6.50

Volitionrx Limited Announces Executive Appointments

Price target raised to US$7.66

Market Sentiment Around Loss-Making VolitionRx Limited (NYSEMKT:VNRX)

New 90-day high: US$4.46